Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways

Approval of checkpoint inhibitors for treatment of metastatic triple negative breast cancer (mTNBC) has opened the door for the use of immunotherapies against this disease. However, not all patients with mTNBC respond to current immunotherapy approaches such as checkpoint inhibitors. Recent evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Michelle M., Hafeez, Sabrina A., Christenson, Jessica L., O’Neill, Kathleen I., Hammond, Nia G., Richer, Jennifer K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622696/
https://www.ncbi.nlm.nih.gov/pubmed/34832904
http://dx.doi.org/10.3390/ph14111122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622696/
https://www.ncbi.nlm.nih.gov/pubmed/34832904
http://dx.doi.org/10.3390/ph14111122

Ejemplares similares